Pelacarsen Roll-over Extension Program

Age: 18 years to 100 years old

Healthy Volunteers:

This study is NOT accepting healthy volunteers

Inclusion Criteria:

* Participants who have provided informed consent prior to initiation of any study-specific activities/procedures. * Participants who have completed the parent study and received the assigned study treatment at the time of its completion

Exclusion Criteria:

* Participants who permanently discontinued the study treatment as mandated per protocol or due to adverse events in the parent study * Any medical condition(s) in the investigator's opinion that may put the participant at risk or interfere with the study participation * Participants who are receiving another investigational drug or device before the open-label treatment period * Participants who have a known sensitivity to the study drug and are deemed as unsuited for the study by the investigator Other protocol-defined inclusion/exclusion criteria may apply.

Interventions:

DRUG: Pelacarsen (TQJ230)

Conditions:

Atherosclerotic Cardiovascular Disease

Keywords:

TQJ230, Lp(a), ASCVD

Contact(s): Novartis Pharmaceuticals - novartis.email@novartis.com

Principal Investigator:

IRB Number:

System ID: NCT06875973

Pelacarsen Roll-over Extension Program

Email this study information to me

Contact the study team